Clinical trial
An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT01063907 is registered in ClinicalTrials.gov with Kyowa Kirin Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Dose Escalation, Multicenter Phase 1/2 Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- March 31, 2010
- Completion date
- November 30, 2013
- Enrollment
- 95 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.